Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts' Corner
NEW YORK, December 24, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Forest Laboratories Inc. (NYSE: FRX), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Alimera Sciences, Inc. (NASDAQ: ALIM), pSivida Corp. (NASDAQ: PSDV), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Forest Laboratories Inc. Research Report
On December 19, 2013, Forest Laboratories Inc. (Forest Laboratories) announced the availability of FETZIMA™ (levomilnacipran ER capsules) in pharmacies throughout the United States. The Company informed that FETZIMA was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder (MDD), also known as depression, in adults in July 2013. Dr. Marco Taglietti, Executive Vice President, Drug Development & Research and Chief Medical Officer of Forest Laboratories commented, "We are pleased to announce that FETZIMA is now available to patients. Despite the number of available antidepressant medications, the treatment of depression remains a clinical challenge with a need for additional treatment options. In clinical studies, patients who received FETZIMA vs. placebo experienced meaningful improvement in their depressive symptoms and functional impairment. The availability of FETZIMA is a significant step forward in our goal of bringing a range of treatment options to adults living with MDD." The Full Research Report on Forest Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Oxygen Biotherapeutics, Inc. Research Report
On December 11, 2013, Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics) announced its selection of Duke University's Duke Clinical Research Institute, (DCRI) to conduct the Phase 3 trial of levosimendan, the Company's newly acquired compound. The Company added that DCRI will serve as the coordinating center and Drs. John H. Alexander and Rajendra Mehta will be lead investigators for the Phase 3 trial. John Kelley, CEO for Oxygen Biotherapeutics commented, "We are extremely pleased to have an organization with the skill and expertise in conducting clinical trials that DCRI possesses as our partner. They have been responsible for managing a number of major cardiac surgery trials in the last decade, so their knowledge of this area of medicine is invaluable to us." According to the Company, Phase 3 trial will be conducted in approximately 50 major cardiac surgery centers in North America, with enrollment expected to begin in the Q3 2014, and will take around 18 months to complete. The Full Research Report on Oxygen Biotherapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Alimera Sciences, Inc. Research Report
On December 18, 2013, Alimera Sciences, Inc. (Alimera) announced that it has entered into labeling discussions with the U.S. Food and Drug Administration (FDA) for ILUVIEN®. The Company added that it has reached an agreement with the FDA that Alimera's participation in the January 2014 Dermatologic and Ophthalmic Advisory Committee meeting was not mandatory, and the Company will focus on drafting its response to the Complete Response Letter received from the FDA in October 2013 for submitting the response in Q1 2014. Dan Myers, President and CEO of Alimera stated, "We are very pleased to have had the opportunity to meet with the FDA to discuss appropriate labeling for ILUVIEN and to determine the next steps required to move ILUVIEN closer to an FDA approval. We are committed to addressing the remaining issues that were raised in the CRL and plan to submit our response in the first quarter of 2014, which will include recent safety data gathered from our patients in Europe." The Full Research Report on Alimera Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
pSivida Corp. Research Report
On December 19, 2013, pSivida Corp.'s (pSivida) stock ended the day at $4.01, representing a 35.02% rise compared to the previous day's closing price of $2.97. The Company's stock rose 42.20% over the past three trading days, compared to the Dow Jones Industrial Average, which went up by 1.85% over the same trading period. The Full Research Report on pSivida Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
AcelRx Pharmaceuticals, Inc. Research Report
On December 19, 2013, AcelRx Pharmaceuticals, Inc. (AcelRx) announced that it has entered into a new amended and restated credit facility with Hercules Technology Growth Capital, Inc. which provides for up to $40 million of new loans. Richard King, President and CEO of AcelRx stated, "The proceeds from this credit facility provide AcelRx with additional operating capital and contingency funding for our commercialization activities as we continue to prepare for the launch, if approved, of Zalviso™. These proceeds also provide the financial flexibility to fund additional pipeline development programs should we decide to advance any of our pipeline opportunities forward. We appreciate the support of Hercules, and its confidence in Zalviso™ and the AcelRx management team." The Full Research Report on AcelRx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.